Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress
-- Late Breaking Presentation of Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne –
-- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design –
- Late breaking clinical data demonstrating the potential of MRI T2 to be a marker for clinical outcome in DMD, titled “A Composite of MRI T2 of Five Lower Leg Muscles Is Highly Correlated with Timed Function Tests and Functional Status and Supports Positive Effects of Edasalonexent in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” will be available in the late breaking poster session throughout the conference.
-
Phase 3 PolarisDMD clinical trial design, titled “Edasalonexent, an
Oral NF-kB Inhibitor, in Development for Treatment of Duchenne
Muscular Dystrophy: The Phase 3 PolarisDMD Study Design,” will be
presented in Poster Session 2 on
Wednesday, October 3, 2018 from 16:00 to 17:30 local time. -
Phase 2 MoveDMD trial and open-label extension data following 72 weeks
of edasalonexent treatment, titled “Edasalonexent, an NF-kB Inhibitor,
Slows Disease Progression Over More Than a Year Compared to Control
Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,”
will be presented in Poster Session 2 on
Wednesday, October 3, 2018 from 16:00 to 17:30 local time.
About Edasalonexent
Edasalonexent (CAT-1004) is an
investigational oral small molecule that is being developed as a
potential new standard of care for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB,
which is the key link between loss of dystrophin and disease
progression. NF-kB has a fundamental role in skeletal and cardiac muscle
disease in DMD. Catabasis is preparing to initiate a single global Phase
3 trial, the PolarisDMD trial, in the second half of 2018 to evaluate
the efficacy and safety of edasalonexent for registration purposes.
Edasalonexent continues to be dosed in an open-label extension of the
MoveDMD Phase 2 clinical trial. The
About Catabasis
At
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005125/en/
Source:
Investor and Media Contact
Catabasis
Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com